ImmuCell Corp
NASDAQ:ICCC
ImmuCell Corp
Research & Development
ImmuCell Corp
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
ImmuCell Corp
NASDAQ:ICCC
|
Research & Development
-$3.1m
|
CAGR 3-Years
12%
|
CAGR 5-Years
6%
|
CAGR 10-Years
-9%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Research & Development
-$8.8B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Research & Development
-$5.7B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Research & Development
-$7.2B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-6%
|
|
|
Astria Therapeutics Inc
NASDAQ:ATXS
|
Research & Development
-$98m
|
CAGR 3-Years
-48%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
-17%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Research & Development
-$3.9B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-15%
|
|
ImmuCell Corp
Glance View
ImmuCell Corp. engages in the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company is headquartered in Portland, Maine and currently employs 60 full-time employees. The firm is engaged in development, acquisition, manufacture and sale of products that improve the health and productivity of dairy and beef cattle. The company manufactures and markets the First Defense product line for the prevention of scours in newborn dairy and beef calves. The company expanded this line into five different products with formulations targeting E. coli and coronavirus pathogens, as well as E. coli, coronavirus and rotavirus pathogens. Its Tri-Shield First Defense product line extension is calf-level, passive antibody product providing immediate immunity against E. coli, coronavirus and rotavirus. These product line provides Immediate Immunity to newborn calves. The firm is engaged in development of Re-Tain, a Nisin treatment for subclinical mastitis in lactating dairy cows. Its products reduce the use of traditional antibiotics in food producing animals.
See Also
What is ImmuCell Corp's Research & Development?
Research & Development
-3.1m
USD
Based on the financial report for Sep 30, 2025, ImmuCell Corp's Research & Development amounts to -3.1m USD.
What is ImmuCell Corp's Research & Development growth rate?
Research & Development CAGR 10Y
-9%
Over the last year, the Research & Development growth was 25%. The average annual Research & Development growth rates for ImmuCell Corp have been 12% over the past three years , 6% over the past five years , and -9% over the past ten years .
